Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 1
1990 3
1991 4
1992 1
1993 1
1994 2
1995 3
1996 4
1997 6
1998 4
1999 7
2000 5
2001 5
2002 3
2003 7
2004 4
2005 10
2006 8
2007 5
2008 7
2009 10
2010 3
2011 8
2012 12
2013 14
2014 18
2015 15
2016 12
2017 20
2018 14
2019 10
2020 13
2021 15
2022 13
2023 12
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Results by year

Filters applied: . Clear all
Page 1
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. Lisio MA, et al. Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952. Int J Mol Sci. 2019. PMID: 30813239 Free PMC article. Review.
Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of …
Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the f …
Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT Jr, Drapkin R. Kroeger PT Jr, et al. Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34. doi: 10.1097/GCO.0000000000000340. Curr Opin Obstet Gynecol. 2017. PMID: 27898521 Free PMC article. Review.
PURPOSE OF REVIEW: The most common type of ovarian cancer, high-grade serous ovarian carcinoma (HGSOC), was originally thought to develop from the ovarian surface epithelium. ...These alterations represent unique therapeutic opportunities in ovarian
PURPOSE OF REVIEW: The most common type of ovarian cancer, high-grade serous ovarian carcinoma (HGSOC), was originally …
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Slomovitz B, et al. Gynecol Oncol. 2020 Mar;156(3):715-725. doi: 10.1016/j.ygyno.2019.12.033. Epub 2020 Jan 20. Gynecol Oncol. 2020. PMID: 31969252 Review.
In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that ma …
In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss t …
Novel therapeutics in low-grade serous ovarian cancer.
Cobb L, Gershenson D. Cobb L, et al. Int J Gynecol Cancer. 2023 Mar 6;33(3):377-384. doi: 10.1136/ijgc-2022-003677. Int J Gynecol Cancer. 2023. PMID: 36878564 Review.
Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer clinically characterized by younger age at diagnosis, relative chemoresistance, and prolonged survival compared with its high-grade serous counterpart. ...In this review, we …
Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer clinically characterized by younger age …
Molecular characteristics and clinical behaviour of epithelial ovarian cancers.
Hollis RL. Hollis RL. Cancer Lett. 2023 Feb 28;555:216057. doi: 10.1016/j.canlet.2023.216057. Epub 2023 Jan 7. Cancer Lett. 2023. PMID: 36627048 Free article. Review.
Ovarian carcinoma (OC) is an umbrella term for multiple distinct diseases (histotypes), each with their own developmental origins, clinical behaviour and molecular profile. ...In particular, reports of genomic characterisation in endometrioid, clear cell, mucinous and low
Ovarian carcinoma (OC) is an umbrella term for multiple distinct diseases (histotypes), each with their own developmental origins, cl
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Moschetta M, George A, Kaye SB, Banerjee S. Moschetta M, et al. Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31. Ann Oncol. 2016. PMID: 27037296 Free article. Review.
Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic ovarian cancers. Up to 50% of HGS ovarian cancer patients may exhibit homologous recombination deficiency (HRD) through mechanisms including germline BRCA m …
Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic ovarian cancers. Up to …
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Bowtell DD, et al. Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Nat Rev Cancer. 2015. PMID: 26493647 Free PMC article. Review.
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. ...This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer A …
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not cha …
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft LE, Dangaj Laniti D, Coukos G. Kandalaft LE, et al. Nat Rev Cancer. 2022 Nov;22(11):640-656. doi: 10.1038/s41568-022-00503-z. Epub 2022 Sep 15. Nat Rev Cancer. 2022. PMID: 36109621 Review.
Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging. Although HGSOC can potentially be responsive to immunotherapy owing to endogenous immunity at the molecular or T cell level, immunotherapy for this disease has fallen short of expectations to …
Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging. Although HGSOC can potentially be responsive to imm …
The Origin of Ovarian Cancer Species and Precancerous Landscape.
Shih IM, Wang Y, Wang TL. Shih IM, et al. Am J Pathol. 2021 Jan;191(1):26-39. doi: 10.1016/j.ajpath.2020.09.006. Epub 2020 Oct 1. Am J Pathol. 2021. PMID: 33011111 Free PMC article. Review.
Unlike other human cancers, in which all primary tumors arise de novo, ovarian epithelial cancers are primarily imported from either endometrial or fallopian tube epithelium. The prevailing paradigm in the genesis of high-grade serous carcinoma (HGSC), the most comm …
Unlike other human cancers, in which all primary tumors arise de novo, ovarian epithelial cancers are primarily imported from either …
The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M, Kang EY. Köbel M, et al. Int J Gynecol Pathol. 2021 Jan;40(1):32-40. doi: 10.1097/PGP.0000000000000725. Int J Gynecol Pathol. 2021. PMID: 33290354 Review.
An important recent development was optimization and validation of p53 IHC, where 3 abnormal IHC patterns (nuclear overexpression, complete absence, cytoplasmic) were shown to predict underlying TP53 mutations with high accuracy in ovarian carcinomas. p53 IHC now helps in …
An important recent development was optimization and validation of p53 IHC, where 3 abnormal IHC patterns (nuclear overexpression, complete …
264 results